VCEL - Vericel Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States

Full Time Employees216

Key Executives

NameTitlePayExercisedYear Born
Mr. Dominick C. Colangelo Esq.CEO, Pres & Director1.07M2.12M1964
Mr. Gerard J. MichelCFO & VP of Corp. Devel.598.54k1.51M1963
Mr. Michael HalpinChief Operating OfficerN/AN/A1961
Ms. Heidi HassenVP of HRN/AN/AN/A
Dr. Jonathan M. HopperChief Medical OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Vericel Corporation’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.